The global heart pump device market size is calculated at USD 3.45 billion in 2024, grew to USD 4.14billion in 2025 and is predicted to hit around USD 21.52 billion by 2034, expanding at a CAGR of 20.10% between 2024 and 2034. The North America heart pump device market size accounted for USD 1.66 billion in 2024 and is representing a notable CAGR of 20.18% during the forecast period.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Heart Pump Device Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Heart Pump Device Market Revenue and Volume, By Type, 2024-2034
8.1.1 Extracorporeal Heart Pump Devices
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Implanted Heart Pump Devices
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Heart Pump Device Market Revenue and Volume, By Product, 2024-2034
9.1.1. Total Artificial Hearts (TAHs)
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Ventricular Assist Devices (VADs)
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Intra-Aortic Balloon Pumps (IABPs)
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Extracorporeal Membrane Oxygenation (ECMO)
9.1.4.1. Market Revenue and Forecast (2021-2034)
10.1. Heart Pump Device Market Revenue and Volume, By Therapy, 2024-2034
10.1.1. Bridge-to-Candidacy (BTC)
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Bridge-to-Transplant (BTT)
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Destination Therapy (DT)
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, By Type (2021-2034)
11.1.2. Market Revenue and Forecast, By Product (2021-2034)
11.1.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, By Type (2021-2034)
11.1.4.2. Market Revenue and Forecast, By Product (2021-2034)
11.1.4.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, By Type (2021-2034)
11.1.5.2. Market Revenue and Forecast, By Product (2021-2034)
11.1.5.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, By Type (2021-2034)
11.2.2. Market Revenue and Forecast, By Product (2021-2034)
11.2.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, By Type (2021-2034)
11.2.4.2. Market Revenue and Forecast, By Product (2021-2034)
11.2.4.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, By Type (2021-2034)
11.2.5.2. Market Revenue and Forecast, By Product (2021-2034)
11.2.5.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, By Type (2021-2034)
11.2.6.2. Market Revenue and Forecast, By Product (2021-2034)
11.2.6.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, By Type (2021-2034)
11.2.7.2. Market Revenue and Forecast, By Product (2021-2034)
11.2.7.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, By Type (2021-2034)
11.3.2. Market Revenue and Forecast, By Product (2021-2034)
11.3.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, By Type (2021-2034)
11.3.4.2. Market Revenue and Forecast, By Product (2021-2034)
11.3.4.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, By Type (2021-2034)
11.3.5.2. Market Revenue and Forecast, By Product (2021-2034)
11.3.5.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, By Type (2021-2034)
11.3.6.2. Market Revenue and Forecast, By Product (2021-2034)
11.3.6.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, By Type (2021-2034)
11.3.7.2. Market Revenue and Forecast, By Product (2021-2034)
11.3.7.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, By Type (2021-2034)
11.4.2. Market Revenue and Forecast, By Product (2021-2034)
11.4.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, By Type (2021-2034)
11.4.4.2. Market Revenue and Forecast, By Product (2021-2034)
11.4.4.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, By Type (2021-2034)
11.4.5.2. Market Revenue and Forecast, By Product (2021-2034)
11.4.5.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, By Type (2021-2034)
11.4.6.2. Market Revenue and Forecast, By Product (2021-2034)
11.4.6.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, By Type (2021-2034)
11.4.7.2. Market Revenue and Forecast, By Product (2021-2034)
11.4.7.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, By Type (2021-2034)
11.5.2. Market Revenue and Forecast, By Product (2021-2034)
11.5.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, By Type (2021-2034)
11.5.4.2. Market Revenue and Forecast, By Product (2021-2034)
11.5.4.3. Market Revenue and Forecast, By Therapy (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, By Type (2021-2034)
11.5.5.2. Market Revenue and Forecast, By Product (2021-2034)
11.5.5.3. Market Revenue and Forecast, By Therapy (2021-2034)
12.1. Abbott
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. ABIOMED
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Berlin Heart
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. BiVACOR Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. CARMAT
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. CorWave SA
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Evaheart, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Fresenius SE & Co. KGaA
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Getinge AB.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Jarvik Heart
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample